Synthetic hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
In this study, we examined the effects of a bolus injection of GHRP on GH release in short patients with or without organic lesions, and subsequently compared the GH secretory profile in the GHRP test with those in other conventional GH stimulation tests.
Materials
and Methods
Subjects
Forty-one patients (12 females and 29 males, aged 8-29 yrs; mean 13 yrs) with short stature (defined as 2.0 SD below the mean for age and sex) were examined.
One patient had undergone operation for pituitary adenoma, and her remaining pituitary had become atrophic on MRI. Four patients had a history of breech delivery, and their pituitary stalks were obviously transsected on MRI. Four other patients had a history of perinatal abnormalities such as asphyxia but, since MRI revealed no organic abnormalities in the hypothalamo-pituitary region, they were counted as patients without organic lesions.
Two patients suffered from Turner syndrome.
The others were short but otherwise normal patients, who showed no abnormalities on brain MRI, and no evidence of chronic disease, genetic bone disease or malnutrition.
In this study, patients with organic lesions were defined as those who had macroscopically visible abnormalities on MRI. All patients were euthyroid at the time of the examination. Patients who were receiving GH therapy stopped injections at least two weeks before the examination.
All the subjects gave informed consent to participate in this study. 3) .
Plasma GH responsiveness to GHRP was not correlated with that to GHRH, L-dopa or insulin. When the plasma GH peak levels after GHRP were compared with those after GHRH, there were eight patients whose GH peaks were less than 10 pg/L after GHRH despite plasma GH rises to more than 10 pet, after GHRP. On the other hand, there were only two patients in whom plasma GH peak levels were less than 10 Ai g/L after GHRP but GHRH could increase plasma GH up to more than 10 pg/L. When plasma GH peaks after GHRP were compared with those after L-dopa or insulin administration, the relation was similar to those after GHRH and GHRP. It was of interest that GHRP failed to increase plasma GH levels in short patients with pituitary transsection (classical pituitary dwarfism) in whom a single injection of GHRH resulted in a slight but significant increase in plasma GH (Fig. 4) . This phenomenon was observed in all four patients [4, 12, 15] . In this study we demonstrated that GHRP consistently stimulated GH secretion as compared with other provocative stimuli such as GHRH, L-dopa and insulinhypoglycemia, and also observed that the plasma GH peaks appeared rapidly, within 45 min after injection, in all the subjects who responded to GHRP. Bowers et al. [16] measured plasma irGHRP levels after GHRP bolus injection and found that it rose immediafter injection and gradually decreased within 20 min of its half-life. The rapid effect of GHRP on plasma GH after administration in short patients is compatible with the evidence that GHRP acts directly on the pituitary. It is of interest that GHRH increased plasma GH levels in short patients with pituitary stalk transsection in whom GHRP failed to cause any increase. Though the reason of this finding remains unclear, it is possible that GHRP might require some other factor from the hypothalamus to exert its full activity in GH Fig 3. Comparison of plasma GH peaks after GHRP and after GHRH, L-dopa, or insulin administration.
There was no correlation beween GH responsiveness to GHRP and that to GHRH, L-dopa or insulin. Open symbols represent patients with organic lesions, and closed symbols represent those without organic lesions. It is important for examination of short subjects to estimate how much GH secretory potency is in reserve as well as to explore the cause of their short stature.
Since most of the patients are children under compulsory education, a safe, rapid and reliable test is desirable to assess the pituitary GH reserve.
GHRP might be a useful agent for this purpose.
